Skip to main content
. 2021 Jun;99(6):435–447. doi: 10.1124/molpharm.120.000207

Fig. 2.

Fig. 2.

RET+ cell lines exhibit differential sensitivity to RET inhibitors. (A) MTS proliferation assays of CUTO22 (blue), CUTO32 (red), CUTO42 (green), and LC-2/Ad (black) cells treated with increasing concentrations of RXDX-105, BLU-667, or ponatinib for 72 hours. Error bars represent means ± S.D. for three replicate experiments. Lower table shows IC50 (nanomolar) values ± S.D. for each inhibitor and cell line. (B) Measurement of apoptosis induction with cleaved caspase 3/7 assay after treatment with increasing concentrations of ponatinib or RXDX-105 for 24 hours. Error bars represent means ± S.D. for three replicate experiments. (C) Western blot analysis of CUTO22, CUTO32, CUTO42, and LC-2/Ad cells treated with increasing concentrations of BLU-667 for 2 hours. pRET = 4G10 anti-phosphotyrosine in LC-2/Ad cells. (D) Quantification of dose-dependent inhibition of pRET with BLU-667. (E) IC50 values for pRET inhibition in immunoblot experiment.